| 2020 |
Cardinal M, Dessain A, Roels T, Lafont S, Ominsky MS, Devogelaer J-P, Chappard D, Mabilleau G, Ammann P, Nyssen-Behets C, Manicourt DH. Sclerostin-antibody treatment decreases fracture rates in axial skeleton and improves the skeletal phenotype in growing oim/oim mice. Calcif Tiss Int. May 2020;106(5):494-508. |
2 |
2 |
| 2020 |
Mieczkowska A, Millar P, Chappard D, Gault VA, Mabilleau G. Dapagliflozin and liraglutide therapies rapidly enhanced bone material properties and matrix biomechanics at bone formation site in a type 2 diabetic mouse model. Calcif Tiss Int. September 2020;107(3):281-293. |
2 |
2 |
| 2020 |
Gobron B, Bouvard B, Vyavahare S, Blom LV, Pedersen KK, Windeløv JA, Boer GA, Harada N, Zhang S, Shimazu‐Kuwahara S, Wice B, Inagaki N, Legrand E, Flatt PR, Chappard D, Hartmann B, Holst JJ, Rosenkilde MM, Irwin N, Mabilleau G. Enteroendocrine K cells exert complementary effects to control bone quality and mass in mice. J Bone Miner Res. July 2020;35(7):1363-1374. |
1 |
1 |
| 2023 |
Gobron B, Couchot M, Irwin N, Legrand E, Bouvard B, Mabilleau G. Development of a first-in-class unimolecular dual GIP/GLP-2 analogue, GL-0001, for the treatment of bone fragility. J Bone Miner Res. May 2023;38(5):733-748. |
0 |
0 |